Top Tweets for #MCSPC
📢 @ASCO #ASCO26: TALAPRO-3 met its primary end point in HRR-altered #mCSPC.
Talazoparib + enzalutamide reduced the risk of radiographic progression or death by 52% vs enzalutamide alone and delivered benefit across BRCA and non-BRCA HRR subgroups.
@neerajaiims @huntsmancancer #medtwitter #oncology #pcsm
https://t.co/kSKuKys2A4
Major adverse cardiovascular events in ARPI-treated patients with #mCSPC. Presentation by Linden Huhmann @DeptVetAffairs. #ASCO26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/FR06kvs0Au @ASCO
Validation of PSA decline among the Latin American Subgroup of #LIBERTAS: A phase 3 study of apalutamide + continuous vs intermittent ADT in #mCSPC. Presentation by Andrea Juliana Gomes. #ASCO26 written coverage by @zklaassen_md > https://t.co/Bf10mYlzni @ASCO
#TALAPRO3: Talazoparib + enzalutamide compared with placebo + enzalutamide for the treatment of patients with #mCSPC harboring HRR gene alterations. Presentation by @neerajaiims @huntsmancancer. #ASCO26 written coverage by @chavarriagaj @PSH_Urology > https://t.co/WApw8pUD62 @ASCO
📢#ASCO26 TALAPRO-3 met its primary endpoint in HRR-altered #mCSPC, with talazoparib + enzalutamide significantly improving rPFS vs enzalutamide alone.
Key findings:
🔹 rPFS HR 0.48 (p<0.0001)
🔹 Benefit observed in both:
• BRCA-altered disease: HR 0.37
• Non-BRCA HRR alterations: HR 0.57
Additional signals:
🔹 Time to PSA progression HR 0.51
🔹 Delayed subsequent therapy HR 0.51
🔹 OS trend favored the combination (HR 0.77)
Importantly, despite higher rates of anemia and hematologic toxicity, PROs remained largely preserved between arms.
@UroToday @ASCO
#ASCO26 @neerajaiims Could #TALAPRO3 establish a new SOC for HRR-mutated #mCSPC Talazoparib + enzalutamide reduced the risk of progression or death by 52% (HR 0.48) ATM 🥇Pending OS @urotoday @SCUColombia @achoHematoYOnco @OncoAlert @Uromigos @oncodaily @ASCO @myESMO @UroOnc
🚨 #ASCO26
**TALAPRO-3** met its primary endpoint. Adding **talazoparib** to **enzalutamide** significantly improved rPFS in patients with HRR-altered metastatic castration-sensitive prostate cancer (#mCSPC).
rPFS: HR 0.48 (52% reduction in risk of progression or death)
BRCA1/2-mutated: HR 0.37
Non-BRCA HRR alterations: HR 0.57
OS trend favored the combination (HR 0.77)
Main AEs: anemia, neutropenia, and fatigue
A practice-changing study highlighting the importance of **early genomic testing** in advanced prostate cancer.
👏 Presented by **Dr. Neeraj Agarwal**
@ASCO @OncoAlert @urotoday
#ProstateCancer #GUOnc #PrecisionOncology #PARPi #Talazoparib #Enzalutamide #HRR #BRCA #ASCO2026 #mCSPC
📌Landmark, phase III #TALAPRO3 trial in #HRRa #mCSPC:
⭕️MET primary endpoint: #talazoparib + #enzalutamide sig improved #rPFS vs ENZA alone (HR 0.48, 95% CI 0.357-0.647, p<0.0001)
▶️Benefit more prominent in BRCA-mutated (HR 0.368) but also seen in nonBRCA-mutated (HR 0.567) subgrouos.
▶️OS trend favored TALA+ENZA
▶️Safety was manageable and consistent with known profiles, though 3 MDS/2 AML
✅️These data lend support to TALA + ENZA in 1L setting for HRR altered mCSPC
#ASCO2026 @ASCO
@TiansterZhang @QianJanieQin @montypal @PGrivasMDPhD @DrChoueiri @neerajaiims @OncoAlert
@neerajaiims PhIII TALAPRO-3 of #ADT + enza +/- talazoparib in #1L HRR-mutant #mCSPC ➡️ improved rPFS in BRCA/non-BRCA-mt pts in tala arm, OS immature, G3-4 TRAEs 79% vs 41% in control, 3 cases MDS & 2 cases AML (tala arm) vs 1 case MDS/AML (control arm)
#ASCO26 @OncoAlert
Dr. Medina retrospective analysis of #CHAARTED ➡️ 26-gene spatial expression model inferred from #H&E slides identifies benefit to addition of #docetaxel to #ADT if biomarker positive in #1L #mCSPC
#ASCO26 @OncoAlert
Real-world characteristics, HRR mutation testing, treatment patterns, and outcomes of patients with #mCSPC in the US community #oncology setting. Upcoming poster presentation by Manojkumar Bupathi, MD, MS. #ASCO26 written coverage by @chavarriagaj > https://t.co/Z66P6X3Z5v
Uptake of doublet and triplet therapy for men with de novo #mCSPC - a population-based study. Presented by Paolo Zaurito, MD @SanRaffaeleMI. #AUA26 written coverage by @chavarriagaj @PSH_Urology > https://t.co/suTfGkAtj8 @AmerUrological
Mañana en el ESMO Summit Latin America 🌎
“Dupletas en mCSPC de Alto Volumen: Datos de Mundo Real para Guiar la Práctica Clínica”
Happy to share this with people I truly admire and appreciate @raymanneh
📍 Bogotá | 17 Abril | 1:00 PM
@ESMO #mCSPC #ESMOSummitLA @Marco_Care_AI
Result never in doubt in #mCSPC #ProstateCancer given design
Questions should focus on short & long term toxicity. Also is sequencing (w/deferred tox) in any way inferior❓
Talazoparib/Enzalutamide Shows Improved Radiographic PFS https://t.co/IpyQdtcT1L
💡Early results from TALAPRO-3 suggest that the combination of talazoparib and enzalutamide may redefine the treatment paradigm for HRR gene-mutated #mCSPC https://t.co/AtEQZLRPPa
Impact of hospitalizations on health-related quality of life and overall survival in #mCSPC: Insights from the #ARANOTE trial. Presented by @CaPsurvivorship @DanaFarber. #GU26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/Fk7TcRyC1b @ASCO
#MEVPRO-3: Phase III trial of mevrometostat + enzalutamide vs placebo + enzalutamide in #mCSPC. Presentation by @neerajaiims @huntsmancancer. #GU26 written coverage by @zklaassen_md @GACancerCenter > https://t.co/yWz8Sm9S1Q @ASCO #ASCOGU26
Safety profile of darolutamide + adt compared to enzalutamide, apalutamide, and abiraterone in #mCSPC #ProstateCancer: results from the first safety matching-adjusted indirect comparison. Presented by Neal Shore, MD, FACS @CURCMB. #GU26 written coverage by @RKSayyid @UAUrology > https://t.co/LmiyckHICi @ASCO
Real-world comparison of PSA response in #mCSPC patients treated with apalutamide without docetaxel vs darolutamide without docetaxel. Presented by @bilenma @EmoryUniversity. #GU26 written coverage by @RKSayyid @UAUrology > https://t.co/UlRZ9TsaWw @ASCO #ASCOGU26
WATCH 👀: @bilenma of @WinshipAtEmory discusses findings from a real-world analysis of apalutamide vs darolutamide in mCSPC.
See the whole video here 📽️: https://t.co/8mf2mbRu7k
#oncology #pcsm #mcspc
Last Seen Hashtags on Sotwe
bop
Seen from United States
nolimit nolimit()*+filter:native_video
Seen from United States
teeNager
Seen from Turkey
متحرر
Seen from Algeria
レールバイク
Seen from United States
家教老师
Seen from United States
冰恋
Seen from United Kingdom
りりあーと
Seen from Japan
ChavitosXXX
Seen from United States
كلبه_مطيعة
Seen from Saudi Arabia
Most Popular Users
Elon Musk 
@elonmusk
241.2M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.9M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.3M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.5M followers
KATY PERRY
@katyperry
89.1M followers
Taylor Swift
@taylorswift13
83M followers
Lady Gaga
@ladygaga
74.5M followers
Virat Kohli
@imvkohli
72M followers
Kim Kardashian
@kimkardashian
70.5M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
64.9M followers
Bill Gates
@billgates
64.6M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62.1M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers